Maximus, Inc.
MMS Details
Maximus, Inc. (NYSE: MMS) is a business process services (BPS) company that specialises in the health and human care sectors. Its business segments are 1) The US Services Segment provides a variety of BPS to US state and local government programmes, such as programme administration, appeals, evaluations, and related consulting services. 2) The US Federal Services Segment provides BPS solutions for a wide range of US federal civilian activities, including system and software development and maintenance. 3) Health and disability assessments, programme management for employment assistance, and other job seeker-related services to governments and commercial customers in countries other than the United States are included in the Outside the US Segment.
Latest News:
- Quarterly Dividend: On April 8, 2022, the company declared a quarterly dividend of USD 0.28 per common share, payable on May 31, 2022, to shareholders of record on May 13, 2022.
Q2FY22 Results:
- Double Digit Growth in Topline: The company reported a YoY growth of 22.73% in overall revenue to USD 1.18 billion in Q2FY22 (ended March 31, 2021) from USD 959.28 million in Q2FY21, driven by 73.65% growth in US Federal Services.
- Reduction in Profitability: In Q2FY22, MMS' net income dropped to USD 50.10 million from USD 80.61 million in Q2FY21.
- Cash and Debt Position: The company had USD 92.64 million in cash and cash equivalents as of March 31, 2022, and total debt of USD 1.45 billion.
Key Risk:
- Competition Risk: MMS competes directly with larger organisations with more significant financial and operational resources in the information technology business. Smaller businesses with established reputations and political ties pose challenges for the company. All of these factors have the potential to hurt MMS' bottom line.
Outlook:
FY22 Guidance (Source: Q2FY22, Earnings Presentation, May 05, 2022)
Valuation Methodology: EV/Sales Multiple Based Relative Valuation
(Analysis by Kalkine Group)
* % Premium/(Discount) is based on our assessment of the company's FY1 trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.
Stock Recommendation:
MMS' stock price has fallen 22.89% in the past nine months and is currently leaning towards the lower end of its 52-week range of USD 63.20 to USD 94.79. We have valued the stock using the EV/Sales-based relative valuation methodology and arrived at a target price of USD 71.45.
Considering the correction in the stock price, positive outlook, associated risks, and current valuation. We recommend a "Hold" rating on the stock at the closing price of USD 64.62, up 0.37% as of May 16, 2022.
Three-Year Technical Price Chart (May 16, 2022). Source: REFINITIV, Analysis by Kalkine Group
Note 1: The reference data in this report has been partly sourced from REFINITIV.
Note 2: All forecasted figures and industry information have been taken from REFINITIV.
Note 3: The report publishing date is as per the Pacific Time Zone.
Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.
Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.
There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.
You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.
The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.
Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.
Please also read our Terms & Conditions and Financial Services Guide for further information.
On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website unless those persons comply with certain safeguards, procedures, and disclosures.
Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.